Johnson D S, Coel M N, Bornemann M
Department of Medicine, University of Hawaii, John A. Burns School of Medicine, Honolulu, USA.
Clin Nucl Med. 2000 Feb;25(2):120-2. doi: 10.1097/00003072-200002000-00008.
Glucagonomas, like other neuroendocrine tumors, express somatostatin receptors in more than 80% of cases. Unfortunately, because of the rarity of these tumors, the sensitivity and specificity of somatostatin analog (octreotide) imaging have not been established. Nonetheless, there have been limited reports in the literature supporting the use of indium In-111 DTPA N-terminal D-phenylalanine (D-PHE1) octreotide for glucagonoma imaging and may be most beneficial as an adjuvant to conventional imaging for tumor staging and therapeutic decision making. Current therapeutic applications of octreotide focus on stabilization of disease in tumors expressing somatostatin receptors, and tumor destruction, using beta-emitting isotopes. In this report, imaging of a glucagonoma with In-111 DTPA-D-PHE1 octreotide scintigraphy is described in a 51-year-old woman examined for a large palpable abdominal mass.
与其他神经内分泌肿瘤一样，超过80%的胰高血糖素瘤表达生长抑素受体。遗憾的是，由于这些肿瘤罕见，生长抑素类似物（奥曲肽）成像的敏感性和特异性尚未确定。尽管如此，文献中已有有限报道支持使用铟In-111二乙三胺五乙酸N端D-苯丙氨酸（D-PHE1）奥曲肽进行胰高血糖素瘤成像，并且作为传统成像的辅助手段用于肿瘤分期和治疗决策制定可能最为有益。奥曲肽目前的治疗应用集中于稳定表达生长抑素受体肿瘤的病情，以及使用发射β射线的同位素破坏肿瘤。在本报告中，描述了一名51岁女性因可触及的腹部巨大肿块接受检查时，使用铟In-111二乙三胺五乙酸-D-PHE1奥曲肽闪烁扫描术对胰高血糖素瘤进行成像的情况。
